X

Trial Profile

A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC).

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dactolisib (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Novartis

Most Recent Events

01 Jul 2016 This was originally designed as a phase Ib/II study; however, no patients were enrolled into the phase II part because of premature closure of the study.
01 Feb 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
09 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com